

Name	: Dr. Rahul G. Ingle
Designation	: Professor
Qualification	: M. Pharm., Ph.D., Post-doc
Specialization	: Pharmaceutical Chemistry
E mail id	: <u>rahul.pharmacy@dmiher.edu.in</u>
Phone	:+91-99-23169327

**Experience** : 12 Years

At present working as a Professor at Datta Meghe College of Pharmacy, DMIMS (DU), Wardha. He has 03 years of academic experience and 06 years of research experience at Roselabs Bioscience, Ahmedabad and Wockhardt Research Centre, Aurangabad (India). In addition, 03 years of post-doctoral experience from the World class Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang University, Hangzhou, China.

## **Research areas**:

- Synthetic Chemistry
- Drug Design
- Analytical Chemistry
- Biopharmaceuticals

## **Research Contributions**

- Research Publications: 29 (International: 25, National-04)
- Books: 03
- Patents: 01 Published
- Paper Presentations: 06 (International: 05, National: 01)
- Industrial Experience
- Sound experience in **RNA synthesis** with **biopharmaceutical formulations** (monoclonal antibodies, **fused proteins, and nucleic acids**) stability study and their analysis.
- Executed industry-based biopharmaceutical projects on various monoclonal antibodies in collaboration with Institute of Innovative Medicine, Hangzhou Biopharma Town, China.
- Performed **forced degradation** studies on **monoclonal antibodies** and their analysis.

- Performed stability studies on various NCE's as per ICH guidelines.
- Screening of quinoxaline derivatives for *in-vivo* anticancer activity on human 60-cell lines from the National Cancer Institute; USA.
- During my industrial carrier; I had worked on enoxaparin (LMWHs), along with billion-dollar antiinfective NCE projects i.e., Nafithromycin, Zidebactam, Levonadifloxacin, ESBL, WCK-771, WCK-5222, WCK-4282, WCK-2349, Tazobactam, etc., which received QIDP approval from US-FDA. In 2020 DCGI, India has approved Emrok (Levonadifloxacin).
- Sound experience at the New Drug Discovery (R&D) Department of Wockhardt Research Centre in drug analysis and testing.
- Handling skills on sophisticated analytical instruments e.g., NMR-400, GC-MS, LC-MS, CHN analyzer, GC, HPLC, MFI, DLS, EPR, FTIR, UV, Polarimeter, Coulometer, KF-Titrator, pH meter, Refractometer, etc.
- During my doctorate, I have synthesized quinoxaline derivatives and collaboratively worked with Tropical Disease Research Centre; MGIMS; Medical College; Sewagram; Wardha for the Infectious Filariasis screening.
- Conferences/Workshops/Seminars attended- 14
- Professional Recognition/ Award/ Prize/ Certificate, Fellowships
- Intellectual Property Rights (IPR), WIPO Geneva, Switzerland.
- Received "Research Fellowship" from All India Council for Technical Education(AICTE), New Delhi, India.
- Qualified GATE Pharmacy 2009, 95 %
- Certificate of Merit, GCOP, Aurangabad.
- Best Cricketer Award, GCOP, Aurangabad.
- Blood Donation Camp Organizer Award, Civil Hospital, Amravati.

## **Recent Publications**

- RD Jawarkar, MEA Zaki, RG Ingle, Application of In-silico Drug Discovery Techniques to Discover a Novel Hit for Target-Specific Inhibition of SARS-CoV-2 Mpro's Revealed Allosteric binding with MAO-B receptor: A theoretical study to Find a cure for post Covid Neurological disorder (PLOS One- Impact factor: 3.75)
- **RG Ingle**, WJ Fang, An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics (**Pharmaceutics- Impact factor: 6.57**)
- RG Ingle, Su Zheng, H, Jiang, WJ Fang, Current development of bioanalytical sample preparation techniques in pharmaceuticals (Journal of Pharmaceutical Analysis-Impact factor: 14.03)
- WJ Fang, **RG Ingle**, JW Liu, XZ Ge, H Wang, Freeze-dried monoclonal antibody formulations are unexpectedly more prone to degradation than liquid formulations under shaking stress (**Journal of Pharmaceutical Sciences- Impact factor: 3.78**)

- **RG Ingle**, WJ Fang, Pre-filled dual-chamber devices (DCDs) Promising high-quality and convenient drug delivery system (**International Journal of Pharmaceutics-Impact factor: 6.51**)
- C. Qian, G. Wang, **RG Ingle**, WJ Fang, Formation of protein sub-visible particles during powder grinding of a monoclonal antibody (**European Journal of Pharmaceutics and Biopharmaceutics- Impact factor: 5.59**)
- VP Rane, RA Jadhav, **RG Ingle**, RD Yeole, Enantiomeric separation and thermodynamic investigation of (R)-5-[1-(4-Nitrobenzylsulfonyloxy)- ethyl]-5-(pyridine-2-yl)- [1,3,4]-thiadiazole, a Key Intermediate of Nafithromycin (**Analytical Chemistry Letters- Impact factor: 1.0**)
- **RG Ingle**, PS Bhoj, R. Reddy, SJ Wadher, K. Goswami, Apoptotic impact on *Brugia malayi* by sulphonamido quinoxaline: search for a novel therapeutic rational (**Parasitology Research Impact factor: 2.57**)
- **RG Ingle**, AS Agrawal, World of low molecular weight heparins (LMWHs): Enoxaparin as a promising moiety—A review (**Carbohydrate Polymers- Impact factor: 10.72**)
- **RG Ingle**, AS Agrawal, Pre-filled syringe a ready-to-use drug delivery system a review (**Expert Opinion on Drug Delivery- Impact factor: 5.55**)
- RG Ingle, DD Magar, RP MArathe, HM Patel, Sulfonamido quinoxaline: Search for anticancer agents (European Journal of Medicinal Chemistry- Impact factor: 7.09)